March 13th 2025
Shionogi’s investigational antiviral is the first COVID-19 oral therapy that has shown this distinction.
March 13th 2025
Sarita Shah, MD, MPH, reveals a decline in timely ART initiation from 86.5% in 2019 to 83.9% in 2020, with viral suppression rates dropping from 91.1% to 84.7%, before showing signs of recovery by 2021.
March 7th 2025
Katherine L Kahn, MD, discusses the impact of restricted access to Paxlovid on hospitalization and mortality rates in a highly vaccinated population.
March 5th 2025
Pemivibart (Pemgarda) demonstrated activity against the LP81 variant.
March 3rd 2025
Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Standard Procedures Protect Health Care Workers from COVID-19, Case Review Shows
March 26th 2020Health care workers involved in aerosol-generating procedures for a patient with unknown COVID-19 were protected from infection with surgical masks and standard procedures, a case review suggests.
Read More
2 Commerce Drive
Cranbury, NJ 08512